| Overview |
| bsm-62953r-100ul |
| PKC delta/theta Recombinant Monoclonal Antibody |
| WB, IHC-P, IHC-F, IF(ICC), IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PKC delta |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Shipped at 4°. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 5580 |
| Q05655,Q04759,P28867 |
| Cytoplasm, Nucleus, Cell membrane |
| ALPS3; CVID9; MAY1; nPKC-delta; nPKC-theta; PKCD; PRKCD; PRKCQ; PRKCT; Protein kinase C delta type; Protein kinase C theta type; SDK1; Sphingosine-dependent protein kinase-1; Tyrosine-protein kinase PRKCD. |
| Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(ICC) |
1:50-200 |
| IF |
|
Powered by Bioz